Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation (Q48292912)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation |
scientific article |
Statements
1 reference
Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation (English)
1 reference
1 reference
Norie Murayama
1 reference
Minako Sugiyama
1 reference
Ken-ichi Fujita
1 reference
Yuko Akiyama
1 reference
Yasutsuna Sasaki
1 reference
25 January 2011
1 reference
39
1 reference
5
1 reference
757-762
1 reference
Identifiers
1 reference